TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04406896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: A single subcutaneous injection of 16 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: A single subcutaneous injection of 16 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: A single subcutaneous injection of 16 mg.
Study: NCT04796363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block with Bubivacaine
Description: Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block with Bubivacaine
Description: Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard General Anaesthesia
Description: Standard General Anaesthesia without ESPB
Study: NCT00797849

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Farabloc Limb Cover
Description: Wear prosthetics, sock or glove laminated with Farabloc

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Limb Cover
Description: Wear prosthetics, sock or glove laminated with sham material
Study: NCT04526223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive treatment regimen
Description: 1. Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF)~2. With at least two month Ruxolitinib treatment prior to transplantation~3. DAC+BF as myeloablative conditioning regimen~4. received Rux at +5d in ASCT and continued to +60d
Study: NCT02915042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Analgesic Efficacy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo
Study: NCT00997282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-262 2.5 mg
Description: orally administered once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-262 5 mg
Description: orally administered once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally administered once daily for 24 weeks
Study: NCT01559272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone IR (Period 1)
Description: Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone IR (Period 1)
Description: Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone IR (Period 1)
Description: Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone IR (Period 1)
Description: Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
Study: NCT00993434

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Booklet on nutrition and physical activity.
Description: Parents will be asked to read the booklet and complete a pre- and post-questionnaire.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Safety Booklet
Description: Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
Study: NCT02043626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEALTH PROMOTION AND MARKETING
Description: SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPPORTUNITIES FOR PHYSICAL ACTIVITY
Description: District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPPORTUNITIES FOR PHYSICAL ACTIVITY
Description: District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
Study: NCT04115800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal Sirolimus
Description: Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
Study: NCT01559272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel A: treatment group 1)
Description: Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel A: treatment group 2)
Description: Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 1)
Description: Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
Study: NCT03217929

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-taVNS
Description: Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
Study: NCT02624284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
Study: NCT02160366

Intervention type: OTHER
Intervention: Biomarker Research
Description: Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
Study: NCT01782313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04061694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading, fully guided surgery and 3D printed restoration
Description: Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immediate loading
Description: Only subjected to immediate loading. Conventional procedure.
Study: NCT01574872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halotherapy
Description: The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
Study: NCT00647699

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
Study: NCT01559272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 2)
Description: Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 3)
Description: Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 4)
Description: Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 5)
Description: Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F016
Description: Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel D: treatment group 1)
Description: Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
Study: NCT00647699

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVA Irradiation
Description: UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
Study: NCT01559272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel D: treatment group 2)
Description: Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel D: treatment group 3)
Description: Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel D: treatment group 4)
Description: Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
Study: NCT00872599

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fenofibrate
Description: Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fenofibrate
Description: Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive placebo or fenofibrate for five days by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
Study: NCT03112265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems
Description: MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring and Feedback System
Description: For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
Study: NCT02093572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 standard meals/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 meals/day (omit breakfast)
Study: NCT01288534

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
Study: NCT01271725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 weekly
Description: Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 40mg once daily (OD)
Description: Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m2 weekly
Description: Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
Study: NCT05482828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JGT (Jaeumgeonbi-Tang) tablet
Description: JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
Study: NCT04230915

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative nerve monitoring
Description: This group will determine as those who were administered 0.3 mg/kg rocuronium,
Study: NCT03488966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Eating and Awareness Training
Description: Eight sessions of Mindfulness Based Eating and Awareness Training (MB-EAT) will be delivered once per week over the course of 8 weeks, following an introductory session. The treatment uses general mindfulness meditation and eating meditation to help participants bring greater awareness and understanding to their relationship with food. Homework consists of weekly mindfulness exercises.
Study: NCT03571126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Olanzapine (10mg/d) (Days1-4)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Placebos (Days1-4)
Study: NCT03854838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolipalimab
Description: Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reirradiation
Description: intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
Study: NCT02618265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobile terminal
Description: multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional management
Description: aspirin or clopidogrel monotherapy or double treatment for

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: website platform management
Description: second prevention based on website platform management
Study: NCT04115800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Sirolimus
Description: Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
Study: NCT01560286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 165 (rAvPAL-PEG)
Description: Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
Study: NCT04377217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video recording
Description: The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months, in order to evaluate the evolution of facial damage. Then algorithms will be developped to be able of differentiating FSHMD patients with facial damage from control subjects using video and audio recordings.
Study: NCT04303481

Intervention type: OTHER
Group type: OTHER
Intervention: normal diet
Description: Control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight loss program kit
Description: Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, and Botanical Liquid Sachet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight loss program kit with A. muciniphila prebiotics
Description: Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, Botanical Liquid Sachet, and Probiotics Liquid Sachet